Monte Rosa Therapeutics, Inc. (GLUE) research
Monte Rosa Therapeutics, Inc.- Sector
- Biotechnology
- Last price
- $10.50
- As of
Monte Rosa Therapeutics, Inc. (GLUE): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-10-01.
As of . Source: SEC EDGAR filings for GLUE. Method and limitations.
Share the GLUE intelligence card
See the full GLUE dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for GLUE on one page. Preview it with sample data, then open it live with a free account.
Preview the GLUE dossierActive signals for GLUE
- highINSTITUTIONAL_EXIT
RENAISSANCE TECHNOLOGIES LLC cut 73% of GLUE (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 55% of GLUE (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +739% to GLUE (2026Q2)
- highINSTITUTIONAL_SURGE
D. E. Shaw & Co., Inc. added +159% to GLUE (2026Q2)
- highINSTITUTIONAL_SURGE
TWO SIGMA INVESTMENTS, LP added +630% to GLUE (2026Q2)
FREE, NO ACCOUNT
Every signal on GLUE, as it fires
You are seeing 5 of 10 signals recorded on GLUE since 2026-05-29.
The five above all landed on 2026-08-16. The other 5 were recorded on 2 other days. 5 of the 10 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in GLUE (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| D. E. Shaw & Co., Inc.CUSIP 61225M102 · 2026Q2 | $4.2M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 61225M102 · 2026Q2 | $4M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 61225M102 · 2026Q2 | $3.4M | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 61225M102 · 2026Q2 | $2.5M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, GLUE
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
GLUE against its peers
GLUE's operating margin of -43.8% ranks in the 50th percentile of 8 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | GLUE | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 124M USD | 94.4M USD | 61 | 8 |
| Operating margin | -43.8% | -70.1% | 50 | 8 |
| Net margin | -31.2% | -77.7% | 50 | 8 |
| Return on equity | -16.6% | -41.0% | 73 | 12 |
Peers (16): MLTX, JANX, CRVS, ABUS, SVRA, KURA, MGTX, MNKD, VOR, CGEM, JBIO, RIGL, TBPH, ARDX, SANA, SGP. Left out: ANL (period gap), ODTX (no annual filing), SPTX (no annual filing), AKTS (no annual filing), SLBT (no annual filing), APMD (no annual filing), IVA (period gap), LTGO (no annual filing), HELP (period gap). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (GLUE: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more GLUE signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to GLUEand get the insider, 13F, options, and confluence read in one view.